secondary cancers, health behaviour and cancer screening adherence in survivors of allogeneic blood...
TRANSCRIPT
![Page 1: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/1.jpg)
Click icon to add picture
![Page 2: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/2.jpg)
Secondary Cancers, Health Behaviour and Cancer Screening Adherence in Survivors of Allogeneic Blood and Marrow Transplant
(BMT) in NSW.
Gemma Dyer, MPH, GradCert Onc, BN, RN
eviQ Content Author and MPhil Student (Usyd)
![Page 3: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/3.jpg)
3
Overview
› 1. Background› 2. The problem› 3. What we did› 4. What we found out › 5. Implications
![Page 4: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/4.jpg)
BackgroundAllogeneic BMT…
4
Proportions of disease indications for an allogeneic HSCT in Europe in 2013
• Worldwide ~ 40,000• Australia = 495 (2013)• NSW = 173 (2013) (35%)
![Page 5: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/5.jpg)
5
Background
Haematopoietic cell transplants by year and type
![Page 6: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/6.jpg)
“The Problem”
oMalignant Disease:
• < 16yrs, 51 – 78%
• > 16yrs, 12 – 68%
oNon-malignant Disease:
• < 16yrs, 95%
• > 16yrs, 43-72%
Survival is improving
10-year Survival (ABMTRR 1998 - 2013)
6
![Page 7: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/7.jpg)
“The problem” of survival post-BMT› Relapse (15-30%)› cGvHD (40-70%)› Cardio-respiratory disease (20-40%)› Endocrinopathies (>60%)› Infertility (Most)› Eye disease (>60%)› Osteoporosis (>40%)› Anxiety and depression, post-trauma› Social dysfunction› Isolation› Secondary cancers (2-8 x)
![Page 8: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/8.jpg)
8
Secondary Cancers and Recommendations for BMT survivors
› 12% cumulative incidence rate at 15 years post BMT
› No plateau
› All cancers have been found to occur post BMT
› Risk Factors:- Young age at BMT
- TBI
- Immunosuppression
- Chronic Graft Versus Host Disease
- Smoking
› International Consensus Guidelines - General population screening
- Healthy lifestyle recommendations
![Page 9: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/9.jpg)
9
General population screening guidelines
› Breast Screen Australia
› National Cervical Screening Program
› National Bowel Cancer Screening Program
› Healthy Behaviors- Quit smoking
- Be ‘sun smart’
- Be active
- Healthy diet
- Limit alcohol intake
![Page 10: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/10.jpg)
Aims
1. Rates of secondary cancers 2. Cancer screening adherence 3. Cancer risk behavior (smoking and drinking)4. Identify barriers to adherence 5. Inform practice and educate BMT survivors
![Page 11: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/11.jpg)
Methods› Sampling frame
- Allogeneic transplant survivors, transplanted between Jan 1 2000 and Dec 31 2012 in NSW
› Instruments- Sydney Post BMT Survey (402 questions, 20 sections)
- FACT-BMT
- cGVHD Activity Assessment
- Lee Chronic GVHD symptom scale
- Post traumatic Growth Inventory
- Fear of Recurrence scale
- Depression, Anxiety & Stress Scale (DASS) 21
- Clinical data form (transplant procedure)
Validated instruments
![Page 12: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/12.jpg)
n=1475Allogeneic BMT
2000-2012
n= 669Allogeneic BMT survivors
806 (55%)Deceased/status
unknown
n= 583 survivors (82.7%) contacted, sent survey
n= 443 survivors (66%)Returned Completed questionnaire
86 Unable to be contacted
17 (3%) declined consent123 surveys not returned
Results
![Page 13: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/13.jpg)
asdasdDemographicsSVariable ResultsMedian survival 5 yrs (Range :1 yr 4 months- 22 yrs)
Median age at survey 54 yrs (Range :19 yrs-79 yrs)
Gender 252 (57%) maleCulture/ethnicity 324 (87%) Australian/European
Education Completed High School (23.6%)Completed University (39.1%)Trade/diploma/part high school (37.3%)
Annual Household income Low <$40,000 (36.5%)Middle $40- <$80,000 (29.2%)High >=$80,000 (34.3%)
Residential location 92% major city/inner regional; 8% outer regional/remote
Relationship status 71% married; 8% defacto21% single/separated/divorced
Results
![Page 14: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/14.jpg)
14
Secondary Cancers post BMT
› 24.1% reported a diagnosis of at least once cancer following BMT
› 21.2% skin cancer
› 1.6% oral cancers
› 4.4% other cancers - Bladder/prostate (4)
- Breast (2)
- Secondary haematological malignancy (3)
- PTLD (1)
- Bowel (1)
- Ovarian (1)
- Sarcoma (1)
- Not specified (4)
![Page 15: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/15.jpg)
15
Health behaviour post BMT
› 7.5% Smokers
› 7.7% Drink alcohol more than recommended amount
› 22.9% Not ‘sun smart’
› 32% Overweight, 16% Obese
› 45.1% Physically active
![Page 16: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/16.jpg)
16
Cancer Screening Adherence post BMT
› 52.4% skin cancer check
› 32.3% bowel cancer check
› 63.4% PAP smear
› 53.3% mammogram
› 36.3% prostate cancer check
In the 2 years since BMT:
![Page 17: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/17.jpg)
17
Barriers to Cancer Screening Adherence post BMT
› 4.4% no time
› 2% cost
› 26% felt it was not necessary
› 72% Not advised by their treatment team
› Factors which increase adherence - Increased time from BMT
- Older age
- Married or defacto relationship (males)
- Higher Quality of Life
Why not?
![Page 18: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/18.jpg)
18
![Page 19: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/19.jpg)
19
Conclusions
› In BMT survivors in NSW:- secondary cancers are common- health risk behaviour is generally better than the general
Australian population health risk behavior- cancer screening adherence is low for this high risk group
![Page 20: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/20.jpg)
20
Implications
› This data should be used develop a Model of Care which is sustainable, cost-effective and consistent with patient needs and preferences:
- Cancer screening needs to be embedded within BMT Long Term Follow Up Care Programs
- This in will hopefully lead to:
- Reduced morbidity and mortality related to secondary cancers post BMT
- Improved Quality of Life post BMT
![Page 21: Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivors of Allogeneic Blood and Marrow Transplant (BMT) in NSW](https://reader035.vdocument.in/reader035/viewer/2022081521/58ee0ee21a28ab92198b4667/html5/thumbnails/21.jpg)
Acknowledgements› Agency for Clinical Innovation BMT Network › BMT Physicians, Researchers, Data Managers, BMT CNCs at each site: › Primary Research Team: Lisa Brice, Nicky Gilroy, Masura Kabir, Ian
Kerridge› RNS: Matthew Greenwood, Kelly Wong, Julian Lindsay, Jennifer Smith,
Chris Poon, Grace Gifford› StVH: John Moore, Jeff Tan, Karim Ibrahim,› RPA: Stephen Larsen, Ann-Marie Johnston, Paris Manii› Westmead: John Kwan, Mark Hertzberg, Megan Hogg, Gillian Huang,
Mark Schifter› Newcastle: Louisa Brown› Patients
21